Login to Your Account

Globeimmune tumbles on GS-4774 miss

Investors watching for signs of M&A activity from Gilead Sciences Inc. could be eyeing the big biotech even more closely after top-line phase II data revealed a missed primary endpoint for HBV contender GS-4774, prompting speculation that the firm could tap other players to shore up its early but promising HBV pipeline. more »

Our Habitat for All Things Science
Search for painkillers comes half-circle

A genomics-based search for better drug targets for painkillers has turned up a candidate that is, in one sense, not new at all.

That candidate is the nicotinic acetylcholine receptor, already the beneficiary of one failed round of drug development.

But the new study, which was published in the May 13, 2015, issue of Science Translational Medicine, suggests that targeting a different subunit of the receptor, and doing so in the periphery, may yield better clinical results.